Search research articles
Contact Us
Filters
Showing results (191-200 of 217) with videos related to
Page
of 22
Sort By:
BMC Cancer
|
July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
Lancet (London, England)
|
December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
Amit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
The Lancet. Digital Health
|
December 10, 2022
Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
Sarah Fremond, Sonali Andani, Jurriaan Barkey Wolf, et al.
Translational Oncology
|
July 1, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial
Pauline Corbaux, Olivier Colomban, Gaelle Lescuyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 8, 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trial
Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev, et al.
The Lancet. Oncology
|
April 3, 2025
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
Toon Van Gorp, Kathleen N Moore, Gottfried E Konecny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trial
Guillaume Beinse, Valerie Taly, Alexandra Leary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation
Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
Nature Communications
|
August 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Florence Joly, Alexandra Leary, Isabelle Ray-Coquard, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 217) with videos related to
Sort By:
Page
of 22
BMC Cancer
|
July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
Lancet (London, England)
|
December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
Amit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
The Lancet. Digital Health
|
December 10, 2022
Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
Sarah Fremond, Sonali Andani, Jurriaan Barkey Wolf, et al.
Translational Oncology
|
July 1, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial
Pauline Corbaux, Olivier Colomban, Gaelle Lescuyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 8, 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trial
Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev, et al.
The Lancet. Oncology
|
April 3, 2025
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
Toon Van Gorp, Kathleen N Moore, Gottfried E Konecny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trial
Guillaume Beinse, Valerie Taly, Alexandra Leary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> Mutation
Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
Nature Communications
|
August 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Florence Joly, Alexandra Leary, Isabelle Ray-Coquard, et al.
Page
of 22